Planet 13 Holdings (PLNH) Research & Development (2021 - 2026)
Planet 13 Holdings' (PLNH) quarterly Research & Development came in at $1.2 million in Q1 2026, down 22.36% year-on-year from $1.5 million in Q1 2025, and up 7.87% on a QoQ basis from $1.1 million in Q4 2025.
Planet 13 Holdings (PLNH) Research & Development (2021 - 2026) Analysis & Trends
Planet 13 Holdings (PLNH) has 6 years of Research & Development data on file, last reported at $1.2 million in Q1 2026.
- On a quarterly basis, Research & Development fell 22.36% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $5.1 million, a 15.68% decrease from a year earlier, with the FY2025 full-year figure at $5.5 million, down 6.0% from the prior year.
- Research & Development for Q1 2026 stood at $1.2 million, up from $1.1 million in the prior quarter.
- Over the last five years, Research & Development for PLNH reached as high as $1.6 million in Q2 2025 and fell as low as $603242.0 in Q1 2022.
- Historically, Research & Development has averaged $1.3 million across 5 years, with a median of $1.3 million in 2023.
- Across the five-year window, Research & Development slumped 52.12% in 2022 and surged 121.43% in 2023, its largest moves.
- Year by year, Research & Development stood at $1.1 million in 2022, then grew by 25.72% to $1.4 million in 2023, then rose by 5.39% to $1.4 million in 2024, then declined by 21.85% to $1.1 million in 2025, then rose by 7.87% to $1.2 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $1.2 million in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 138.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Planet 13 Holdings | 39.35 Mn | 23.09 Mn | 9.41 Mn | 1.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.20 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.63 Mn |
| Mar 31, 2025 | 1.55 Mn |
| Dec 31, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 1.52 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Dec 31, 2023 | 1.35 Mn |
| Sep 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | 1.33 Mn |
| Mar 31, 2023 | 1.34 Mn |
| Dec 31, 2022 | 1.08 Mn |
| Sep 30, 2022 | 938,269.00 |
| Jun 30, 2022 | 887,436.00 |
| Mar 31, 2022 | 603,242.00 |
| Dec 31, 2021 | 1.81 Mn |
| Sep 30, 2021 | 1.96 Mn |
| Jun 30, 2021 | 1.54 Mn |